Highlights

  • Kromek Group reported H1 2025/26 revenue of GBP 15.0 m, up from GBP 3.7 m a year earlier.
  • Adjusted EBITDA improved to GBP 6.0 m and profit before tax reached GBP 3.1 m, reversing prior-year losses.
  • KMK shares dropped 8.7% today to 10.50 GBX, despite a 128% increase in the past 12 months.

Kromek Group plc (LSE:KMK) shares fell 8.7%, trading at 10.50 GBX at the time of writing on 20 January 2026, following the release of the company’s unaudited interim results for the six months ended 31 October 2025. The technology company, which develops radiation and bio-detection solutions for advanced imaging and CBRN (chemical, biological, radiological, nuclear) detection, has seen its share price rise 128% over the past year.

Notably, the share price has jumped 128% in a year.

Revenue and Profit Surge

Kromek reported a substantial increase in revenue to GBP 15.0 m, compared with GBP 3.7 m in H1 2025.

  • Advanced Imaging: Revenue reached GBP 10.8 m, or GBP 2.5 m excluding Siemens Healthineers’ contribution, marking a 41% rise on an underlying basis.
  • CBRN Detection: Revenue more than doubled to GBP 4.3 m from GBP 2.0 m, driven by government and international orders.
  • Profit Metrics: Adjusted EBITDA reached GBP 6.0 m, compared with a GBP 2.3 m loss in H1 2025, and profit before tax improved to GBP 3.1 m from a GBP 5.7 m loss the prior year.

The company held GBP 1.2 m in cash at 31 October 2025 and had secured a GBP 6.0 m revolving credit facility, with GBP 1.0 m drawn, along with a GBP 0.5 m asset finance facility to support growth initiatives.

Operational Developments

Advanced Imaging Progress

Kromek’s Advanced Imaging segment benefited from landmark agreements with Siemens Healthineers for the production of cadmium zinc telluride (CZT) detectors used in SPECT systems. Deliveries under collaboration agreements with Tier 1 OEMs, including Analogic Corporation and Spectrum Dynamics, supported the growth. The company continues its commercialisation of photon-counting computed tomography (PCCT) detectors, with validation trials underway at a leading US medical clinic funded by Innovate UK.

CBRN Detection Expansion

The CBRN Detection segment grew due to government contracts and expanded distributor networks. Notable orders include GBP 1.7 m under the UK Government’s Radiological Nuclear Detection Framework and a GBP 250k contract with the UK Ministry of Defence’s Defence Science and Technology Laboratory for developing advanced biological agent detection methods. Orders were also received globally, from the UK, Europe, the US, Japan, Canada, and Australasia.

Manufacturing and IP

Production capacity expansion and automation improved productivity and cost efficiency. The Group filed three new patents and had three more granted, bringing total patents to over 190.